

Insulin Action in the Brain and the Pathogenesis of Alzheimer's Disease

C. Ronald Kahn and Ryo Suzuki

Abstract Over 24 million people in the U.S. have diabetes mellitus, and about 90% of these have the type 2 form of the disease. In addition, an estimated 40–60 million people have pre-type 2 diabetes, impaired glucose tolerance or the cluster of abnormalities referred to variably as the metabolic syndrome or syndrome X (Reaven 1988). In all of these disorders, a central component of the pathophysiology is insulin resistance. Insulin resistance is also closely linked to other common health problems, including obesity, polycystic ovarian disease, hyperlipidemia, hypertension and atherosclerosis (Biddinger and Kahn 2006). Recent data also indicate a link between insulin resistance, type 2 diabetes and Alzheimer's disease (Craft 2007). Cross-sectional studies have suggested an association between type 2 diabetes and cognitive decline, especially in aspects of verbal memory (Strachan et al. 1997). Longitudinal studies have revealed that patients with type 2 diabetes have a 1.5-fold greater change over time in measures of cognitive function than those without diabetes (Cukierman et al. 2005). While some of this change may certainly be due to the increased prevalence of atherosclerosis in diabetic patients, there is increasing evidence that insulin resistance itself may affect CNS function and risk of Alzheimer's disease. In this review we will explore this relationship, focusing on experiments we have performed in mice.

1 The Insulin Signaling System

The insulin/IGF-1 signaling system is evolutionarily very ancient. Homologues of these receptors have been identified in *Drosophila*, *C. elegans*, *Porifera* and many other species (Petruzzelli et al. 1986; Skorokhod et al. 1999; Dorman et al. 1995;

C.R. Kahn (✉)

Joslin Diabetes Center and Harvard Medical School, One Joslin Place, Boston, MA 02215, USA
e-mail: c.ronald.kahn@joslin.harvard.edu

Renteria et al. 2008). The insulin receptor (IR) was initially identified using ^{125}I -insulin binding (Freychet et al. 1972). Biosynthetic and affinity labeling revealed the IR to be glycoproteins, consisting of two 135 kDa α -subunits and two ~ 95 kDa β -subunits linked by disulfide bonds to form an $\alpha_2\beta_2$ heterotetramer (Massague et al. 1980; Kasuga et al. 1982a). On pulse-chase labeling, both subunits were derived from a single chain precursor or proreceptor (Hedo et al. 1983). In 1982, we demonstrated that the IR possessed tyrosine kinase activity, placing it biochemically in the family of receptor tyrosine kinases and opening up new avenues in the study of insulin signaling (White et al. 1987; Kasuga et al. 1982b). In 1985, two groups succeeded in cloning the cDNA of the human IR, confirming these structural features (Ullrich et al. 1985; Ebina et al. 1985).

The IR gene is present on chromosome 19p13.3 in humans and chromosome 8 in the mouse. In both, the gene is >120 kb in length and is composed of 22 exons, which to some extent encode functional domains of the receptor (Fig. 1). The IR cDNA in both humans and rodents possesses an open reading frame of 4,146 nucleotides that encodes the 1,382-amino acid precursor of the receptor (Ullrich et al. 1985; Ebina et al. 1985), including a 27-amino acid signal peptide, a 721-amino acid α -subunit, a four-amino acid processing site, and a β -subunit of 619 amino acids. During the biosynthesis of the proreceptor, both subunits undergo glycosylation, disulfide bond formation and proteolytic cleavage by a furin-related protease to give the mature receptor (Hedo et al. 1983).

Functionally, the IR behaves as a classic allosteric enzyme. The α -subunit of the IR serves as both the insulin binding subunit and the regulatory subunit. Insulin binding to the α -subunit induces conformational changes in the receptor and activates the kinase activity in the β -subunit. The β -subunit is a transmembrane protein linked by disulfide bonds to the α -subunit and contains the tyrosine kinase activity critical for insulin action (Kasuga et al. 1982b). Following stimulation, the β -subunit undergoes autophosphorylation on seven Tyr residues in an ordered cascade; three of these at Tyr 1158, 1162, 1163 result in activation of the receptor kinase toward other substrates (Feener et al. 1993; Hubbard 1997). The IR occurs as two splice variants based on inclusion (IR-B) or exclusion (IR-A) of a 12-residue segment encoded by exon 11 and inserted between residues 716 and 717 (IR-A numbering) near the C-terminus of the α -subunit. In the brain, the major isoform of the insulin receptor is the A isoform (Kenner et al. 1995). The molecular weights of the denatured α - and β -subunits from brain insulin receptors are 5-10 kDa smaller than their counterparts in other tissues, which appears to be due to differences in N-linked glycosylation (Heidenreich et al. 1983). Whether they are differences in IR isoform splicing or glycosylation in Alzheimer's brain versus normal brain has not been studied.

cDNA cloning and functional studies have revealed two other members of the IR family: the highly homologous IGF-1 receptor (Ullrich et al. 1986; Abbott et al. 1992) and the IR-related receptor (IRR; Shier and Watt 1989; Zhang and Roth 1992). Insulin, IGF-1 and IGF-2 can bind to both the IR and IGF-1R, albeit with differing affinities. No ligand has thus far been identified for the IRR, and thus its physiological function is unknown. All three receptors are normally disulfide-linked




Fig. 1 Modular structure of insulin receptor (IR) gene and protein. Schematic of the $\alpha_2\beta_2$ structure of the IR. On the left, the half-receptor heterodimer is depicted by its genomic structure, which is encoded by the 22-exon sequences. On the right, the half-receptor heterodimer is depicted by predicted protein modules. L1: large domain 1; CR: cystein-rich domain; L2: large domain 2; Fn: fibronectin type III domains; Ins: Insert; TM: transmembrane domain; JM: juxtamembrane domain; TK: tyrosine kinase domain; CT: C-terminal domain. The orange arrowheads indicate the N-glycosylation sites. Adapted from De Meyts and Whittaker (2002)

homodimers but may also function as heterodimer hybrids, like IR/IGF-1R hybrids, in tissues that express both receptors (Slaaby et al. 2006; Benyoucef et al. 2007). IGF-1 receptors are abundant in brain and widely distributed therein and they have a somewhat different distribution from IRs (Dore et al. 1997; Baron Van Evercooren et al. 1991). IRR mRNA is also found in brain, but its distribution is

highly restricted to the forebrain, primarily cholinergic neurons and neurons that coexpress *trkA*, a high-affinity receptor for nerve growth factor (Tsuji et al. 1996).

2 Linking the Receptor to the Insulin and IGF-1 Signaling Pathways

Following ligand binding, the activated IRs and IGF-1 receptors initiate signaling networks that share many similarities and critical nodes of signal divergence and regulation (Taniguchi et al. 2006; Fig. 2). The primary action of these receptors is to phosphorylate a family of at least 12 intracellular substrate proteins. The first four of these identified were designated IRS-1 to IRS-4 (IR substrates 1-4; Taniguchi et al. 2006; White 1998). These IRS proteins are 60 to 180 kDa and are characterized by a pleckstrin homology (PH) domain, a phosphotyrosine binding (PTB) domain, which account for their high affinity for the IR, and up to 20 potential tyrosine phosphorylation sites spread throughout the molecule. All four IRS proteins have been identified in brain, although the major forms appear to be IRS-1 and




Fig. 2 Signaling networks of insulin and IGF-I receptors. The insulin and IGF-1 signaling networks are complex and contain at least three critical nodes. The three major nodes in this pathway are the IR coupled to IRS proteins (purple box), PI 3-Kinase (green box), and Akt (blue box). Plain arrows represent an activation process, blocked arrows represent an inhibition process, and dashed arrows represent an activation process with less intensity. Cytokine (TNF α , IL6, leptin) signaling pathways have been shown to interfere with insulin signaling and are also represented on this figure (orange and red arrows). Adapted from Taniguchi et al. (2006)

IRS-2, similar to most insulin-sensitive tissues. Other direct substrates of the insulin/IGF-1 receptor kinases include the various isoforms of Shc, DOK-4 and DOK-5 (also referred to as IRS-5 and IRS-6), Gab-1, p62dok, Cbl, FAK, Sam68, DAPP1, and CEACAM1 (Ribon et al. 1998; Poy et al. 2002; Najib and Sanchez-Margalet 2002; Okamura-Oho et al. 2001; Wick et al. 2001; Cai et al. 2003). Following phosphorylation, these substrates function as key intermediates in signal transduction by interacting with other intracellular molecules. The best-characterized of these are SH2 domain proteins that bind to phosphotyrosines in specific sequence motifs on the IRS proteins. These SH2 proteins fall into two major categories: adaptor molecules, such as the regulatory subunit of PI 3-kinase, Grb2, which associates with SOS to activate the Ras-MAP kinase pathway (Baltensperger et al. 1993; Valverde et al. 2001), CrkII (Karas et al. 2001) and Nck2 (Tu et al. 2001), and enzymes, such as the phosphotyrosine phosphatase SHP2 (Rocchi et al. 1996) and the tyrosine kinase Fyn (Sun et al. 1996). The IRS proteins also interact with proteins that do not contain SH2 domains, including the calcium ATPases SERCA 1 and 2 (Algenstaedt et al. 1997), SV40 large T antigen (Prisco et al. 2002), Rho-kinases (Begum et al. 2002), PH domain-interacting protein (PHIP; Farhang-Fallah et al. 2000), IRAS (Sano et al. 2002) and others (Kruger et al. 2008; Hanke and Mann 2009). Through extensive studies, each of these has been shown to play important roles in the downstream actions of insulin and IGF-1, with the enzyme PI 3-kinase forming the most important link in insulin signaling to its metabolic effects (reviewed in Taniguchi et al. 2006).

In addition to these primary pathways of insulin/signal transduction, there are a number of other pathways activated, including pathways involving Cbl, CAP and the GTPase TC10 (Ribon et al. 1998; Chang et al. 2007), activation of GTPase of the Rac and Rho family (Usui et al. 2003), and interactions with the adaptor protein APS (Barres et al. 2006). Indeed, in collaboration with Mathias Mann using phosphoproteomics, we have identified as many as 40 proteins involved in insulin/IGF-1 action via tyrosine phosphorylation (Kruger et al. 2008).

3 Regulation of the IRS and IGF-1 Receptors in Physiology and Pathophysiology

The insulin/IGF-1 signaling pathway is subject to regulation at multiple levels in normal physiology and disease states. Over 100 patients with syndromes of severe insulin resistance have been reported with mutations in the IR gene (Taylor et al. 1994; Rouard et al. 1999). In addition to mutation, there are a number of mechanisms that play a role in acquired alterations of IR signaling in disease. The most common mechanism is down-regulation of the IR, which occurs to variable degrees in all hyperinsulinemic states (Gavin et al. 1974; Haft et al. 1994). This down-regulation occurs through internalization and subsequent degradation of the receptor. It is not clear if the brain shows similar down-regulation of the IR in obesity and

type 2 diabetes in humans; in rodents, studies on this point have provided conflicting results (Figlewicz et al. 1986; Havrankova et al. 1979)

In addition to changes in receptor concentration, inhibition of receptor kinase activity can occur in diabetes and obesity secondary to phosphorylation of the IR or its substrates by serine kinases activated by increased levels of cytokines, such as TNF α and IL-6 (Hotamisligil et al. 1993; Fernandez-Real et al. 2000; Takayama et al. 1988). IR and IGF-1 receptor function may also be modified by protein-protein interaction. Interacting proteins include the suppressors of cytokine signaling (SOCS) proteins (Emanuelli et al. 2000; Ueki et al. 2004), the growth factor receptor-bound proteins Grb10 and Grb14 (He et al. 1998; Kasus-Jacobi et al. 1998) and PC-1, also termed ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1; Goldfine et al. 2008).

4 Creation and Characterization of the Brain IR Knockout Mouse

IRs are present on virtually all tissues in mammals, including the classic insulin-responsive tissues (muscle, fat and liver) and non-classical tissues, such as brain, β -cells, endothelial cells, etc. A major initiative of the past 10 years was based on the use of the Cre-*lox* system to create tissue-specific IR knockout (KO) mice and to use these to define more precisely the role of insulin action in each tissue of the body. Since IRs are widely distributed throughout the central nervous system (CNS; Havrankova et al. 1978) and have been suggested to play a role in feeding behavior (Schwartz et al. 2000), we decided to study the physiological role of insulin in the brain. We created mice with a neuron-specific disruption of the IR gene (NIRKO mice) using the nestin promoter (Bruning et al. 2000). Inactivation of the brain IR had no impact on brain development but, as expected, resulted in a loss of insulin-stimulated PIP₃ in the hypothalamus, while response to leptin remained normal (Fig. 3, top; Schubert et al. 2004). As a result of CNS insulin resistance, NIRKO




Fig. 3 Loss of insulin signaling in brain-specific IR knockout (NIRKO) mice. The ability of the brain to respond to peripherally administered insulin and leptin is demonstrated by an increase in PIP₃ staining in the paraventricular region. Stimulation by insulin is lost in the brain of the NIRKO mouse, whereas stimulation by leptin remains active. Adapted from Shubert et al. (2004)

mice showed increased food intake, and both male and female mice developed diet-sensitive obesity, with increases in body fat and plasma leptin levels, mild insulin resistance, elevated insulin levels, and hypertriglyceridemia (Fig. 3, middle). In addition, loss of insulin action in the CNS had an effect on liver metabolism. Thus, while peripheral insulin suppressed hepatic glucose production by 74% in control mice, insulin action on hepatic glucose production (HGP) was markedly blunted in NIRKO mice (Fig. 4, bottom; Fisher et al. 2005). This finding is complementary to those of Rossetti and Accili that insulin action on the brain can regulate hepatic glucose output (Obici et al. 2002; Okamoto et al. 2004). In NIRKO mice, insulin-stimulated brain glucose uptake was reduced $\sim 46\%$,




Fig. 4 Metabolic phenotypes of brain-specific IR knockout (NIRKO) mice. Knockout of the IR in the brain results in mild hyperphagia and obesity with increased leptin levels and increased plasma insulin levels (Panel a). WT: wild type; KO: knockout. The hyperglycemia is due to a defect in insulin's ability to suppress hepatic glucose output (Panel b). Adapted from Bruning et al. (2000)

whereas glucose transport in muscle or fat was not altered. Finally, NIRKO mice exhibited defects in counter-regulatory response to hypoglycemia, especially increases in epinephrine and nor-epinephrine (Fisher et al. 2005), and impaired testicular and ovarian function due to hypothalamic hypogonadism (Bruning et al. 2000). Thus, IR signaling in the CNS plays an important role in regulation of appetite, energy disposal, hepatic metabolism, hypoglycemic counter-regulation and reproduction.

To define the specific cells in the brain involved in control of metabolism, in collaboration with Jens Bruning, we generated mice with selective inactivation of the IR in pro-opiomelanocortin (POMC) or agouti-related peptide (AgRP)-expressing neurons (Konner et al. 2007). While neither POMC- nor AgRP- IR KO mice exhibited obesity or altered energy homeostasis, IR KO in AgRP neurons resulted in a loss of insulin's ability to normally suppress HGP. AgRP-IRKO mice also exhibited reduced hepatic IL-6 expression and increased hepatic expression of glucose-6-phosphatase. In addition, we created two mouse models with inducible IR inactivation, one in the whole body including brain (IR Δ wb) and a second restricted to peripheral tissues (IR Δ per) (Koch et al. 2008). While both strains developed severe hyperinsulinemia, hyperglycemia was more pronounced in IR Δ wb mice, consistent with the additional role of insulin action in brain control of glucose metabolism also observed by Accili (Okamoto et al. 2004). Interestingly, the IR Δ wb mice also had a more pronounced reduction in the white adipose tissue (WAT) mass than IR Δ per, suggesting an additional role of central insulin action in control of fat mass (Koch et al. 2008).

5 Impairment of insulin Signaling in Brain is Linked to Neurodegenerative Disease

There is a growing body of evidence linking insulin resistance and insulin action in the brain to neurodegenerative disease, especially Alzheimer's disease (Craft 2007). Low concentrations of insulin and reduced receptor numbers and signaling events in the CNS with Alzheimer's disease have been reported (Frolich et al. 1998; Hoyer 2002). Insulin administration while maintaining euglycemia improves memory in both healthy adults and Alzheimer's disease patients (Craft et al. 1999). In addition to Alzheimer's disease, Parkinson's disease is reported to accompany insulin resistance with a high prevalence (Pressley et al. 2003). Likewise, some studies have found that patients with Huntington's disease have a higher prevalence of diabetes and insulin resistance (Farrer 1985). Since insulin has neuroprotective effects in vivo (Hui et al. 2005; Rizk et al. 2006; Collino et al. 2009), impaired insulin action in the brain may have a critical role for pathogenesis of those neurodegenerative diseases.

One specific potential molecular link between insulin and neurodegeneration is the enzyme glycogen synthase kinase 3 (GSK3; Hooper et al. 2008). GSK3 activity

is negatively modulated by insulin via an activation of Akt. GSK3 induces the hyperphosphorylation of Tau in vitro, and its overexpression in the adult brain of conditional transgenic mice causes Tau-hyperphosphorylation and neurodegeneration (Lucas et al. 2001).

To directly determine whether the brain IR is an important regulator of GSK3 in vivo, we performed additional studies in NIRKO mice. These studies revealed a markedly reduced phosphorylation of Akt and GSK3 β in the brains of NIRKO mice leading to a parallel and substantial increase in Tau-phosphorylation (Fig 5, bottom right); Schubert et al. 2004). In vitro neurons of NIRKO mice exhibit a complete loss of insulin-mediated activation of PI 3-kinase and inhibition of neuronal apoptosis. Thus, lack of insulin signaling in neurons can induce some markers of neurodegeneration and increased susceptibility to cell death. Nevertheless, NIRKO mice exhibit no alteration in neuronal survival or memory function measured by water maze test (Schubert et al. 2004), suggesting that, for development of Alzheimer's disease, some other mechanisms might be crucial besides insulin signal deficiency in the brain. Surprisingly, one model of Alzheimer's disease, the Tg2576 Swedish amyloid precursor protein mutant-overexpressing transgenic, shows improvement in premature mortality or A β deposition when the mice lack IGF-1 receptor or IRS-2 in the hippocampus (Freude et al. 2009; Killick et al. 2009); in this model, IR deficiency did not affect mortality (Freude et al. 2009). These data suggest distinct roles for IRs and IGF-1 receptors in the hippocampus and in the pathogenesis of Alzheimer's disease.




Fig. 5 Altered GSK3 and Tau phosphorylation in brain-specific IR knockout (NIRKO) mice. The left panel shows reduced GSK3 β phosphorylation in the NIRKO mouse brain as determined by immunoblotting. Since phosphorylation decreases GSK3 β activity, this decrease would correspond to increased kinase activity. The right panel shows increased Tau threonine-231 phosphorylation, which is presumably the result of the increased GSK3 β activity. Increased Tau phosphorylation is a marker of abnormalities in Alzheimer's disease. Adapted from Schubert et al. (2004)

6 Insulin-degrading Enzyme in Pathogenesis of Alzheimer's Disease and Metabolic Diseases

Another potential candidate that links insulin resistance/diabetes and Alzheimer's disease is insulin-degrading enzyme (IDE). More than 50 years ago, Mirsky and Broh-Kahn described "insulinase," a 110 kDa zinc metalloendopeptidase present in liver extract (Mirsky and Broh-Kahn 1948). This enzyme, currently named IDE or insulysin, is highly expressed in the brain, testis and muscle, as well as in the liver (Kuo et al. 1993). IDE is predominantly cytosolic, with smaller amounts in peroxisomes, endoplasmic reticulum and plasma membranes (Miners et al. 2008). Interestingly, up to 10% fraction of the total IDE is trafficked to the extracellular space, despite its lack of a classical signal peptide, presumably via an unconventional protein secretion pathway (Zhao et al. 2009). Several peptides with molecular weights of 3-10 kDa have been shown to serve as the substrates of IDE, including insulin, IGF-I, IGF-II, amylin, and A β . The peptide substrates share little to no homology of primary amino acid sequence but have a similar secondary structure with "amyloidogenic" character (Qiu and Folstein 2006), as demonstrated by recent crystallographic data (Shen et al. 2006).

Levels of IDE protein and transcripts are reduced in the hippocampi from Alzheimer's disease patients with an apolipoprotein E (apoE)- ϵ 4 allele compared to either patients without this allele or normal subjects (Cook et al. 2003). A recent report exhibited that A β degradation extracellularly by IDE is facilitated by apoE (Jiang et al. 2008). The IDE region of chromosome 10q has been shown to have genetic linkage to late-onset Alzheimer's disease (Bertram et al. 2000). A lot of evidence indicates that the same region of chromosome 10q is also genetically linked to type 2 diabetes (Saxena et al. 2007; Zeggini et al. 2007). In addition, a well-characterized rat model of type 2 diabetes, Goto-Kakizaki (GK), has been found to harbor two missense mutations in IDE gene that decrease its ability to degrade both insulin and A β (Fakhrai-Rad et al. 2000; Farris et al. 2004). Furthermore, genetic disruption of IDE gene in mice causes increased levels of cerebral A β and glucose intolerance with hyperinsulinemia (Farris et al. 2003).

Because of the strong A β -degrading ability of IDE, defects in IDE activity in the brain can be a direct trigger of A β deposition to develop Alzheimer's disease (Fig. 6). Several reports suggest that insulin signaling regulates IDE expression. Incubation with insulin increases IDE protein in primary hippocampal neurons, whereas reduction of PI 3-kinase p85 subunit is correlated with a decrease of IDE in human Alzheimer's disease brains and in Tg2576 transgenic mice fed a high-fat diet (Zhao et al. 2004). Insulin-deficient diabetes induced by streptozotocin (STZ) administration also reduces IDE protein in the brain (Jolivald et al. 2008). Thus, secondary reduction of IDE caused by insufficient insulin action in the brain might accelerate onset of Alzheimer's disease.

In contrast, insulin-resistant/glucose-intolerant phenotypes of IDE-deficient rodents and a genetic linkage of human IDE chromosomal region with type 2 diabetes susceptibility strongly suggest that IDE has a role in maintaining




Fig. 6 Hypothetical mechanism of insulin resistance caused by IDE insufficiency. IR bound with insulin receives internalization. IDE degrades the ligand insulin at endosome. Free receptor is transferred to membrane and recycled (top). When IDE is functional, sufficient numbers of receptors are recycled to the cell surface, and the downstream signal maintains expression of IDE (bottom left). In case IDE has insufficient function, ligand-bound IRs are trapped and unable to be transferred/recycled. Reduction of available IR causes insulin resistance, and consequent impairment of insulin action causes IDE downregulation, which aggravates IDE insufficiency as a “vicious cycle”

insulin sensitivity in the body. However, the mechanism remains unclear. IDE knockout mice have about a 3-fold increase in fasting insulin levels in plasma (Farris et al. 2003), possibly as a consequence of reduced insulin degradation, but hyperinsulinemia itself does not always cause systemic insulin resistance or impaired glucose tolerance (Hennige et al. 2003). Fakhrai-Rad proposed a hypothesis that a decreased intracellular degradation of insulin bound to its receptor would inhibit receptor-mediated signal transduction by lowering the number of available receptors on the cell membrane and/or compromising the downstream signaling from the receptor (Fakhrai-Rad et al. 2000). When either IDE or IR has a defective activity a priori or posteriori, mutual regulation between IDE and insulin action in the CNS may behave as a “vicious cycle” that may trigger development of cognitive dysfunction and onset of Alzheimer’s disease in diabetes patients (Fig. 6).

7 Insulin, Diabetes, and Brain Cholesterol Metabolism

Insulin plays a crucial role for glucose homeostasis, cell survival, and lipid metabolism. Both type 1 and type 2 diabetes are frequently accompanied by dyslipidemia, which can occur as a consequence of alterations in lipogenesis, lipoprotein secretion, and lipolysis in the body. A number of studies have been reported concerning the effects of insulin on circulating lipid or lipid contents in the peripheral tissues. However, lipid metabolism, especially cholesterol in the CNS with insulin resistance/diabetes, is not yet well characterized in spite of its potential importance.

In preliminary studies, we have observed a possible connection between insulin action in the brain and cholesterol metabolism. In studies using Affymetrix microarrays to identify genes differentially expressed in the hypothalami from STZ-diabetic mice (a model of type 1 diabetes), *ob/ob* mice (a model of type 2 diabetes) and NIRKO mice, a model of CNS insulin resistance we found that the cholesterol biosynthesis pathway was one of the most highly regulated gene sets in the hypothalamus of the STZ-diabetic mouse, with a decrease in expression of cholesterol synthesis-related genes (Fig. 7).

The brain is the most cholesterol-rich organ, containing approximately 25% of the cholesterol present in the body. Disturbances of intracellular cholesterol




Fig. 7 Suppression of a cholesterol synthetic gene in streptozotocin-induced diabetes mouse brain. Expression of HMG-CoA reductase (HMGCR), a rate-limiting enzyme for cholesterol biosynthesis, was measured using RNA from hypothalami of brains from control mice, mice with streptozotocin (STZ)-induced diabetes (a model of type 1 diabetes) and *ob/ob* mice (a model of obesity and type 2 diabetes) using quantitative real-time PCR. Data are expressed relative to control levels of 1.0

metabolism by gene mutations cause some congenital diseases, i.e., Smith-Lemli-Opitz syndrome (DHCR7 gene) and Niemann-Pick disease type C (NPC1 and NPC2 genes), which exhibit CNS manifestations including mental retardation. The majority of cholesterol present in the CNS resides in two different pools, the myelin sheaths of oligodendroglia and the plasma membranes of astrocytes and neurons. It has been estimated that up to 70% of the brain cholesterol is associated with myelin (Bjorkhem and Meaney 2004). Although neurons are capable of synthesizing cholesterol, it has been suggested that, in the adult state, neurons rely on delivery of cholesterol from nearby cells such as astrocytes (Mauch et al. 2001; Pfrieger 2003). Many studies indicate that cholesterol content in neurons is crucial for biogenesis of the synaptic vesicles (Thiele et al. 2000; Hering et al. 2003) and their exocytosis (Chamberlain et al. 2001; Lang et al. 2001; Mitter et al. 2003). Cholesterol delivered to neurons is thought to be important in synaptogenesis and may be incorporated into synaptic vesicles. For the delivery of cholesterol, apoE-containing lipoproteins serve as cholesterol carriers. Transcripts for apoE are distributed throughout all regions of the brain and are localized to astrocytes and microglia (Beffert et al. 1998).

A growing body of evidence now implicates a possible link between cholesterol and neurodegenerative disorders, including Alzheimer's disease (Canevari and Clark 2007). The earliest observation of the link was the recognition of apo E- ϵ 4 allele as an important risk factor for late-onset Alzheimer's disease (Corder et al. 1993). The association between diabetes and Alzheimer's disease is especially strong among carriers of the apo E- ϵ 4 allele (Peila et al. 2002). Furthermore, possible associations have been reported between Alzheimer's disease and polymorphisms within the lipoprotein-related protein 1 (LRP1) gene (Kang et al. 1997; Lendon et al. 1997), or HMG-CoA reductase (HMGCR) gene (Park et al. 2003; Recuero et al. 2009), strengthening the putative relationship between cholesterol biology and Alzheimer's disease.

The role of cholesterol in Alzheimer's disease has been controversial for a long time (Shobab et al. 2005; Ledesma and Dotti 2006; Jaeger and Pietrzik 2008). One controversy is about the possible beneficial effect of cholesterol-lowering statins in reducing the risk of Alzheimer's disease. Early case-control studies suggested that statin use was associated with a significant decrease in prevalence of Alzheimer's disease or dementia. However, several recent prospective cohort studies did not find any significant decrease in incidence of Alzheimer's disease or dementia among statin users (Shobab et al. 2005). Multiple *in vitro* studies have identified a role for cholesterol in promoting A β production, but not all results are consistent (Abad-Rodriguez et al. 2004; Park et al. 2003; Liu et al. 2007). A significant reduction of brain cholesterol in Alzheimer's disease patients has been observed, particularly in areas loaded with amyloid plaques (Ledesma et al. 2003). It is possible that the heterogeneity of Alzheimer's disease pathology makes the questions very complicated. Further studies examining the potential reduction of cholesterol synthesis in brains with diabetes may provide insights into one mechanism of reduced synapse plasticity in diabetes (Biessels et al. 1996; Kamal et al. 2006) and pathogenesis of cognitive dysfunction in diabetes patients.

References

- Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B, Dotti CG (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. *J Cell Biol* 167:953–960
- Abbott AM, Bueno R, Pedrin MT, Murray JM, Smith RJ (1992) Insulin-like growth factor I receptor gene structure. *J Biol Chem* 267:10759–10763
- Algenstaedt P, Antonetti DA, Yaffe MB, Kahn CR (1997) Insulin receptor substrate proteins create a link between the tyrosine phosphorylation cascade and the Ca²⁺-ATPases in muscle and heart. *J Biol Chem* 272:23696–23702
- Baltensperger K, Kozma LM, Cherniack AD, Klarlund JK, Chawla A, Banerjee U, Czech MP (1993) Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes. *Science* 260:1950–1952
- Baron Van Evercooren A, Olichon-Berthe C, Kowalski A, Visciano G, Van Obberghen E (1991) Expression of IGF-I and insulin receptor genes in the rat central nervous system: a developmental, regional, and cellular analysis. *J Neurosci Res* 28:244–253
- Barrès R, Gremeaux T, Gual P, Gonzalez T, Gugenheim J, Tran A, Marchand-Brustel Y, Tanti JF (2006) Enigma interacts with adaptor protein with PH and SH2 domains to control insulin-induced actin cytoskeleton remodeling and glucose transporter 4 translocation. *Mol Endocrinol* 20:2864–2875
- Beffert U, Danik M, Krzywkowski P, Ramassamy C, Berrada F, Poirier J (1998) The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. *Brain Res Brain Res Rev* 27:119–142
- Begum N, Sandu OA, Ito M, Lohmann SM, Smolenski A (2002) Active Rho kinase (ROK- α) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. *J Biol Chem* 277:6214–6222
- Benyoucef S, Surinya KH, Hadaschik D, Siddle K (2007) Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. *Biochem J* 403:603–613
- Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE (2000) Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. *Science* 290:2302–2303
- Biddinger SB, Kahn CR (2006) From mice to men: insights into the insulin resistance syndromes. *Annu Rev Physiol* 68:123–158
- Biessels GJ, Kamal A, Ramakers GM, Urban IJ, Spruijt BM, Erkelens DW, Gispen WH (1996) Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. *Diabetes* 45:1259–1266
- Bjorkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. *Arterioscler Thromb Vasc Biol* 24:806–815
- Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR (2000) Role of brain insulin receptor in control of body weight and reproduction. *Science* 289:2122–2125
- Cai D, Dhe-Paganon S, Melendez PA, Lee J, Shoelson SE (2003) Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. *J Biol Chem* 278:25323–25330
- Canevari L, Clark JB (2007) Alzheimer's disease and cholesterol: the fat connection. *Neurochem Res* 32:739–750
- Chamberlain LH, Burgoyne RD, Gould GW (2001) SNARE proteins are highly enriched in lipid rafts in PC12 cells: implications for the spatial control of exocytosis. *Proc Natl Acad Sci USA* 98:5619–5624
- Chang L, Chiang SH, Saltiel AR (2007) TC10 α is required for insulin-stimulated glucose uptake in adipocytes. *Endocrinology* 148:27–33

- Collino M, Aragno M, Castiglia S, Tomasinelli C, Thiemermann C, Boccuzzi G, Fantozzi R (2009) Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3 β . *Diabetes* 58:235–242
- Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E- ϵ 4 allele. *Am J Pathol* 162:313–319
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261:921–923
- Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. *Curr Alzheimer Res* 4:147–152
- Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. *Arch Gen Psychiat* 56:1135–1140
- Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. *Diabetologia* 48:2460–2469
- De Meyts P, Whittaker (2002) Structural biology of insulin and IGF-I receptors: implications from drug design. *Nature Rev Struct Biol* 1:769–783
- Dore S, Kar S, Rowe W, Quirion R (1997) Distribution and levels of [125I]IGF-I, [125I]IGF-II and [125I]insulin receptor binding sites in the hippocampus of aged memory-unimpaired and -impaired rats. *Neuroscience* 80:1033–1040
- Dorman JB, Albinder B, Shroyer T, Kenyon C (1995) The age-1 and daf-2 genes function in a common pathway to control the lifespan of *Caenorhabditis elegans*. *Genetics* 141:1399–1406
- Ebina Y, Ellis L, Jarnagin K, Edery M, Graf L, Clauser E, Ou J-H, Masiar F, Kan YW, Goldfine ID, Roth RA, Rutter WJ (1985) The human insulin receptor cDNA: The structural basis for hormone activated transmembrane signalling. *Cell* 40:747–758
- Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. *J Biol Chem* 275:15985–15991
- Fakhrai-Rad H, Nikoshkov A, Kamel A, Fernstrom M, Zierath JR, Norgren S, Luthman H, Galli J (2000) Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. *Human Mol Genet* 9:2149–2158
- Farhang-Fallah J, Yin X, Trentin G, Cheng AM, Rozakis-Adcock M (2000) Cloning and characterization of PHIP, a novel insulin receptor substrate-1 pleckstrin homology domain interacting protein. *J Biol Chem* 275:40492–40497
- Farrer LA (1985) Diabetes mellitus in Huntington disease. *Clin Genet* 27:62–67
- Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid β -protein, and the β -amyloid precursor protein intracellular domain in vivo. *Proc Natl Acad Sci USA* 100:4162–4167
- Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ (2004) Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid β -protein. *Am J Pathol* 164:1425–1434
- Feener EP, Backer JM, King GL, Wilden PA, Sun XJ, Kahn CR, White MF (1993) Insulin stimulates serine and tyrosine phosphorylation in the juxtamembrane region of the insulin receptor. *J Biol Chem* 268:11256–11264
- Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M, Richart C, Ricart W (2000) Interleukin-6 gene polymorphism and insulin sensitivity. *Diabetes* 49:517–520
- Figlewicz DP, Ikeda H, Hunt TR, Stein LJ, Dorsa DM, Woods SC, Porte D, Jr. (1986) Brain insulin binding is decreased in Wistar Kyoto rats carrying the 'fa' gene. *Peptides* 7:61–65
- Fisher SJ, Bruning JC, Lannon S, Kahn CR (2005) Insulin signaling in the central nervous system is critical for the normal sympathoadrenal response to hypoglycemia. *Diabetes* 54:1447–1451

- Freude S, Hettich MM, Schumann C, Stohr O, Koch L, Kohler C, Udelhoven M, Leeser U, Muller M, Kubota N, Kadowaki T, Krone W, Schroder H, Bruning JC, Schubert M (2009) Neuronal IGF-1 resistance reduces A β accumulation and protects against premature death in a model of Alzheimer's disease. *FASEB J*
- Freychet P, Roth J, Kahn CR, Neville DM, Jr. (1972) Insulin-receptor interaction in the liver: Specific binding of 125I-insulin to the plasma membrane. In: INSERM (ed) Colloque sur les Hormones Pancreatiques. Paris, France, pp. 335–357
- Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Turk A, Hoyer S, Zochling R, Boissl KW, Jellinger K, Riederer P (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. *J Neural Transm* 105:423–438
- Gavin JR, III, Roth J, Neville DM, Jr., De Meyts P, Buell DN (1974) Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. *Proc Natl Acad Sci USA* 71:84–88
- Goldfine ID, Maddux BA, Youngren JF, Reaven G, Accili D, Trischitta V, Vigneri R, Frittitta L (2008) The role of membrane glycoprotein plasma cell antigen 1/ectonucleotide pyrophosphatase phosphodiesterase 1 in the pathogenesis of insulin resistance and related abnormalities. *Endocr Rev* 29:62–75
- Haft CR, Klausner RD, Taylor SI (1994) Involvement of dileucine motifs in the internalization and degradation of the insulin receptor. *J Biol Chem* 269:26286–26294
- Hanke S, Mann M (2009) The phosphotyrosine interactome of the insulin receptor family and its substrates IRS-1 and IRS-2. *Mol Cell Proteomics* 8:519–534
- Havrankova J, Roth J, Brownstein M (1978) Insulin receptors are widely distributed in the central nervous system of the rat. *Nature* 272:827–829
- Havrankova J, Roth J, Brownstein MJ (1979) Concentrations of insulin and insulin receptors in the brain are independent of peripheral insulin levels. Studies of obese and streptozotocin-treated rodents. *J Clin Invest* 64:636–642
- He W, Rose DW, Olefsky JM, Gustafson TA (1998) Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains. *J Biol Chem* 273:6860–6867
- Hedo JA, Kahn CR, Hayashi M, Yamada KM, Kasuga M (1983) Biosynthesis and glycosylation of the insulin receptor. Evidence for a single polypeptide precursor of the two major subunits. *J Biol Chem* 258:10020–10026
- Heidenreich KA, Zahniser NR, Berhanu P, Brandenburg D, Olefsky JM (1983) Structural differences between insulin receptors in the brain and peripheral target tissues. *J Biol Chem* 258:8527–8530
- Hennige AM, Burks DJ, Ozcan U, Kulkarni RN, Ye J, Park S, Schubert M, Fisher TL, Dow MA, Leshan R, Zakaria M, Mossa-Basha M, White MF (2003) Upregulation of insulin receptor substrate-2 in pancreatic beta cells prevents diabetes. *J Clin Invest* 112:1521–1532
- Hering H, Lin CC, Sheng M (2003) Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. *J Neurosci* 23:3262–3271
- Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. *J Neurochem* 104:1433–1439
- Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor- α : Direct role in obesity-linked insulin resistance. *Science* 259:87–91
- Hoyer S (2002) The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. *J Neural Transm* 109:991–1002
- Hubbard SR (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. *EMBO J* 16:5572–5581
- Hui L, Pei DS, Zhang QG, Guan QH, Zhang GY (2005) The neuroprotection of insulin on ischemic brain injury in rat hippocampus through negative regulation of JNK signaling pathway by PI3K/Akt activation. *Brain Res* 1052:1–9

- Jaeger S, Pietrzik CU (2008) Functional role of lipoprotein receptors in Alzheimer's disease. *Curr Alzheimer Res* 5:15–25
- Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE promotes the proteolytic degradation of A β . *Neuron* 58:681–693
- Jolivalt CG, Lee CA, Beiswenger KK, Smith JL, Orlov M, Torrance MA, Masliah E (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. *J Neurosci Res* 86:3265–3274
- Kamal A, Biessels GJ, Gispen WH, Ramakers GM (2006) Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats. *Brain Res* 1073–1074:276–280
- Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R (1997) Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. *Neurology* 49:56–61
- Karas M, Koval AP, Zick Y, LeRoith D (2001) The insulin-like growth factor I receptor-induced interaction of insulin receptor substrate-4 and Crk-II. *Endocrinology* 142:1835–1840
- Kasuga M, Hedo JA, Yamada KM, Kahn CR (1982a) The structure of the insulin receptor and its subunits: Evidence for multiple non-reduced forms and a 210K possible prореceptor. *J Biol Chem* 257:10392–10399
- Kasuga M, Karlsson FA, Kahn CR (1982b) Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. *Science* 215:185–187
- Kasus-Jacobi A, Perdereau D, Auzan C, Clauser E, Van Obberghen E, Mauvais-Jarvis F, Girard J, Burnol AF (1998) Identification of the rat adapter Grb14 as an inhibitor of insulin actions. *J Biol Chem* 273:26026–26035
- Kenner KA, Kusari J, Heidenreich KA (1995) cDNA sequence analysis of the human brain insulin receptor. *Biochem Biophys Res Commun* 217:304–312
- Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine EE, Choudhury AI, Drinkwater L, Kerr F, Al Qassab H, Stephenson J, Yilmaz Z, Giese KP, Brion JP, Withers DJ, Lovestone S (2009) Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. *Biochem Biophys Res Commun* 386:257–262
- Koch L, Wunderlich FT, Seibler J, Konner AC, Hampel B, Irlenbusch S, Brabant G, Kahn CR, Schwenk F, Bruning JC (2008) Central insulin action regulates peripheral glucose and fat metabolism in mice. *J Clin Invest* 118:2132–2147
- Konner AC, Janoschek R, Plum L, Jordan SD, Rother E, Ma X, Xu C, Enriori P, Hampel B, Barsh GS, Kahn CR, Cowley MA, Ashcroft FM, Bruning JC (2007) Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. *Cell Metab* 5:438–449
- Kruger M, Kratchmarova I, Blagoev B, Tseng YH, Kahn CR, Mann M (2008) Dissection of the insulin signaling pathway via quantitative phosphoproteomics. *Proc Natl Acad Sci USA* 105:2451–2456
- Kuo WL, Montag AG, Rosner MR (1993) Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues. *Endocrinology* 132:604–611
- Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C, Jahn R (2001) SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. *EMBO J* 20:2202–2213
- Ledesma MD, Dotti CG (2006) Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for? *FEBS Lett* 580:5525–5532
- Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, Dingwall C, Dotti CG (2003) Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. *EMBO Rep* 4:1190–1196
- Lendon CL, Talbot CJ, Craddock NJ, Han SW, Wragg M, Morris JC, Goate AM (1997) Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. *Neurosci Lett* 222:187–190

- Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. *Neuron* 56:66–78
- Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. *EMBO J* 20:27–39
- Massague J, Pilch PF, Czech MP (1980) Electrophoretic resolution of three major insulin receptor structures with unique subunits stoichiometries. *Proc Natl Acad Sci USA* 77:7137–7141
- Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieder FW (2001) CNS synaptogenesis promoted by glia-derived cholesterol. *Science* 294:1354–1357
- Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Abeta-degrading enzymes in Alzheimer's disease. *Brain Pathol* 18:240–252
- Mirsky IA, Broh-Kahn RH (1948) The role of insulinase in the regulation of carbohydrate metabolism. *J Clin Invest* 27:549
- Mitter D, Reisinger C, Hinz B, Hollmann S, Yelamanchili SV, Treiber-Held S, Ohm TG, Herrmann A, Ahnert-Hilger G (2003) The synaptophysin/synaptobrevin interaction critically depends on the cholesterol content. *J Neurochem* 84:35–42
- Najib S, Sanchez-Margalet V (2002) Sam68 associates with the SH3 domains of Grb2 recruiting GAP to the Grb2-SOS complex in insulin receptor signaling. *J Cell Biochem* 86:99–106
- Obici S, Zhang BB, Karkanias G, Rossetti L (2002) Hypothalamic insulin signaling is required for inhibition of glucose production. *Nature Med* 8:1376–1382
- Okamoto H, Nakae J, Kitamura T, Park BC, Dragatsis I, Accili D (2004) Transgenic rescue of insulin receptor-deficient mice. *J Clin Invest* 114:214–223
- Okamura-Oho Y, Miyashita T, Yamada M (2001) Distinctive tissue distribution and phosphorylation of IRSp53 isoforms. *Biochem Biophys Res Commun* 289:957–960
- Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, Jung MW, Bang OY, Kim SU, Mook-Jung I (2003) Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. *Neurobiol Aging* 24:637–643
- Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. *Diabetes* 51:1256–1262
- Petrzell L, Herrera R, Arenas Garcia R, Fernandez R, Birnbaum MJ, Rosen OM (1986) Isolation of a Drosophila genomic sequence homologous to the kinase domain of the human insulin receptor and detection of the phosphorylated Drosophila receptor with an anti-peptide antibody. *Proc Natl Acad Sci USA* 83:4710–4714
- Pfrieder FW (2003) Role of cholesterol in synapse formation and function. *Biochim Biophys Acta* 1610:271–280
- Poy MN, Yang Y, Rezaei K, Fernstrom MA, Lee AD, Kido Y, Erickson SK, Najjar SM (2002) CEACAM1 regulates insulin clearance in liver. *Nat Genet* 30:270–276
- Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S, Mayeux R (2003) The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. *Neurology* 60:87–93
- Prisco M, Santini F, Baffa R, Liu M, Drakas R, Wu A, Baserga R (2002) Nuclear translocation of insulin receptor substrate-1 by the simian virus 40 T antigen and the activated type 1 insulin-like growth factor receptor. *J Biol Chem* 277:32078–32085
- Qiu WQ, Folstein MF (2006) Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. *Neurobiol Aging* 27:190–198
- Reaven GM (1988) Banting lecture: Role of insulin resistance in human disease. *Diabetes* 37:1595–1607
- Recuero M, Vicente MC, Martinez-Garcia A, Ramos MC, Carmona-Saez P, Sastre I, Aldudo J, Vilella E, Frank A, Bullido MJ, Valdivieso F (2009) A free radical-generating system induces the cholesterol biosynthesis pathway: a role in Alzheimer's disease. *Aging Cell* 8:128–139

- Renteria ME, Gandhi NS, Vinuesa P, Helmerhorst E, Mancera RL (2008) A comparative structural bioinformatics analysis of the insulin receptor family ectodomain based on phylogenetic information. *PLoS ONE* 3:e3667
- Ribon V, Printen JA, Hoffman NG, Kay BK, Saltiel AR (1998) A novel, multifunctional c-Cbl binding protein in insulin receptor signaling in 3T3-L1 adipocytes. *Mol Cell Biol* 18:872–879
- Rizk NN, Rafols JA, Dunbar JC (2006) Cerebral ischemia-induced apoptosis and necrosis in normal and diabetic rats: effects of insulin and C-peptide. *Brain Res* 1096:204–212
- Rocchi S, Tartare-Deckert S, Sawka-Verhelle D, Gamha A, Van Obberghen E (1996) Interaction of SH2-containing protein tyrosine phosphatase 2 with the insulin receptor and the insulin-like growth factor-I receptor: Studies of the domains involved using the yeast two-hybrid system. *Endocrinology* 137:4944–4952
- Rouard M, Bass J, Grigorescu F, Garrett TP, Ward CW, Lipkind G, Jaffiole C, Steiner DF, Bell GI (1999) Congenital insulin resistance associated with a conformational alteration in a conserved beta-sheet in the insulin receptor L1 domain. *J Biol Chem* 274:18487–18491
- Sano H, Liu SC, Lane WS, Piletz JE, Lienhard GE (2002) Insulin receptor substrate 4 associates with the protein IRAS. *J Biol Chem* 277:19439–19447
- Saxena R, Voight BF, Lyssenko V, Burt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson BK, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Tewhey R, Blumenstiel B, Parkin M, DeFelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science* 316:1331–1336
- Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Kustermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC (2004) Role for neuronal insulin resistance in neurodegenerative diseases. *Proc Natl Acad Sci USA* 101:3100–3105
- Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. *Nature* 404:661–671
- Shen Y, Joachimiak A, Rosner MR, Tang WJ (2006) Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism. *Nature* 443:870–874
- Shier P, Watt VM (1989) Primary structure of a putative receptor for a ligand of the insulin family. *J Biol Chem* 264:14605–14608
- Shobab LA, Hsiung GY, Feldman HH (2005) Cholesterol in Alzheimer's disease. *Lancet Neurol* 4:841–852
- Skorokhod A, Gamulin V, Gundacker D, Kavsan V, Muller IM, Muller WE (1999) Origin of insulin receptor-like tyrosine kinases in marine sponges. *Biol Bull* 197:198–206
- Slaaby R, Schaffer L, Lautrup-Larsen I, Andersen AS, Shaw AC, Mathiasen IS, Brandt J (2006) Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. *J Biol Chem* 281:25869–25874
- Strachan MW, Deary IJ, Ewing FM, Frier BM (1997) Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. *Diabetes Care* 20:438–445
- Sun XJ, Pons S, Asano T, Myers MG, Jr., Glasheen EM, White MF (1996) The fyn tyrosine kinase binds IRS-1 and forms a distinct signaling complex during insulin stimulation. *J Biol Chem* 271:10583–10587
- Takayama S, White MF, Kahn CR (1988) Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. *J Biol Chem* 263:3440–3447
- Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. *Nat Rev Mol Cell Biol* 7:85–96

- Taylor SI, Wertheimer E, Accili D, Cama A, Hone J, Roach P, Quon MJ, Suzuki Y, Levy-Toledano R, Taouis M, Luz Sierra M, Barbetti F, Gorden P (1994) Mutations in the insulin receptor gene: update. *Endocr Rev* 2:58–65
- Thiele C, Hannah MJ, Fahrenholz F, Huttner WB (2000) Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. *Nature Cell Biol* 2:42–49
- Tsuji N, Tsujimoto K, Takada N, Ozaki K, Ohta M, Itoh N (1996) Expression of insulin receptor-related receptor in the rat brain examined by in situ hybridization and immunohistochemistry. *Brain Res Mol Brain Res* 41:250–258
- Tu Y, Liang L, Frank SJ, Wu C (2001) Src homology 3 domain-dependent interaction of Nck-2 with insulin receptor substrate-1. *Biochem J* 354:315–322
- Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. *Mol Cell Biol* 24:5434–5446
- Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M, Mason A, Seeburg PH, Grunfeld C, Rosen OM, Ramachandran J (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. *Nature* 313:756–761
- Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E (1986) Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. *EMBO J* 5:2503–2512
- Usui I, Imamura T, Huang J, Satoh H, Olefsky JM (2003) Cdc42 is a Rho GTPase family member that can mediate insulin signaling to glucose transport in 3T3-L1 adipocytes. *J Biol Chem* 278:13765–13774
- Valverde AM, Mur C, Pons S, Alvarez AM, White MF, Kahn CR, Benito M (2001) Association of insulin receptor substrate 1 (IRS-1) Y895 with Grb-2 mediates the insulin signaling involved in IRS-1-deficient brown adipocyte mitogenesis. *Mol Cell Biol* 21:2269–2280
- White MF (1998) The IRS-signalling system: a network of docking proteins that mediate insulin action. *Mol Cell Biochem* 182:3–11
- White MF, Stegmann EW, Dull TJ, Ullrich A, Kahn CR (1987) Characterization of an endogenous substrate of the insulin receptor in cultured cells. *J Biol Chem* 262:9769–9777
- Wick MJ, Dong LQ, Hu D, Langlais P, Liu F (2001) Insulin receptor-mediated p62dok tyrosine phosphorylation at residues 362 and 398 plays distinct roles for binding GTPase-activating protein and Nck and is essential for inhibiting insulin-stimulated activation of Ras and Akt. *J Biol Chem* 276:42843–42850
- Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B, Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS, McCarthy MI, Hattersley AT (2007) Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science* 316:1336–1341
- Zhang B, Roth RA (1992) The insulin receptor-related receptor: tissue expression, ligand binding specificity, and signaling capabilities. *J Biol Chem* 267:18320–18328
- Zhao J, Li L, Leissring MA (2009) Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. *Mol Neurodegener* 4:4
- Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. *J Neurosci* 24:11120–11126